NO20045220L - Heterocykliske inhibitorer for kinaser - Google Patents

Heterocykliske inhibitorer for kinaser

Info

Publication number
NO20045220L
NO20045220L NO20045220A NO20045220A NO20045220L NO 20045220 L NO20045220 L NO 20045220L NO 20045220 A NO20045220 A NO 20045220A NO 20045220 A NO20045220 A NO 20045220A NO 20045220 L NO20045220 L NO 20045220L
Authority
NO
Norway
Prior art keywords
kinases
heterocyclic inhibitors
heterocyclic
inhibitors
Prior art date
Application number
NO20045220A
Other languages
English (en)
Other versions
NO330043B1 (no
Inventor
Rajeev S Bhide
Robert M Borzilleri
Zhen-Wei Cai
Ligang Qian
John S Tokarski
Peter Zheng
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20045220L publication Critical patent/NO20045220L/no
Publication of NO330043B1 publication Critical patent/NO330043B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20045220A 2002-06-20 2004-11-29 Heterocykliske forbindelser, farmasoytiske preparater innholdende slike samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom NO330043B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39081302P 2002-06-20 2002-06-20
PCT/US2003/019243 WO2004001059A2 (en) 2002-06-20 2003-06-18 Heterocyclic inhibitors of kinases

Publications (2)

Publication Number Publication Date
NO20045220L true NO20045220L (no) 2005-01-19
NO330043B1 NO330043B1 (no) 2011-02-07

Family

ID=30000629

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045220A NO330043B1 (no) 2002-06-20 2004-11-29 Heterocykliske forbindelser, farmasoytiske preparater innholdende slike samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom

Country Status (14)

Country Link
US (2) US7084160B2 (no)
EP (1) EP1513818B1 (no)
JP (1) JP4477492B2 (no)
AR (1) AR040272A1 (no)
AT (1) ATE455767T1 (no)
AU (1) AU2003251559A1 (no)
DE (1) DE60331061D1 (no)
ES (1) ES2337246T3 (no)
IS (1) IS7599A (no)
NO (1) NO330043B1 (no)
PE (1) PE20040581A1 (no)
PL (1) PL374272A1 (no)
TW (1) TW200401638A (no)
WO (1) WO2004001059A2 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
EP0977563B1 (en) * 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
WO2004003179A1 (en) * 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4791183B2 (ja) * 2002-08-23 2011-10-12 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロン、その中間体、類似体の合成およびその使用
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1653951B1 (en) 2003-07-11 2011-12-28 Merck Patent GmbH Benzimidazole derivatives as raf kinase inhibitors
BRPI0415467A (pt) 2003-10-23 2006-12-19 Ab Science compostos de 2-aminoariloxazol para o tratamento de doenças
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7449167B2 (en) * 2004-07-08 2008-11-11 Air Products And Chemicals, Inc. Catalyst and process for improving the adiabatic steam-reforming of natural gas
SG171690A1 (en) 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
CN101217954B (zh) * 2005-04-04 2013-07-10 Ab科学公司 经取代的噁唑衍生物及其作为酪氨酸激酶抑制剂的用途
WO2006134989A1 (ja) * 2005-06-15 2006-12-21 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
WO2007067257A2 (en) 2005-12-02 2007-06-14 Vanderbilt University Broad-emission nanocrystals and methods of making and using same
AU2006328882B2 (en) 2005-12-21 2011-06-16 Amgen Research (Munich) Gmbh Pharmaceutical antibody compositions with resistance to soluble CEA
JP2009520782A (ja) * 2005-12-22 2009-05-28 アストラゼネカ アクチボラグ 化合物
EP2010168B1 (en) 2006-02-14 2014-04-16 The President and Fellows of Harvard College Histone deacetylase inhibitors
EP1991247B1 (en) 2006-02-14 2015-10-14 President and Fellows of Harvard College Bifunctional histone deacetylase inhibitors
EP2004614B1 (en) * 2006-04-13 2016-10-19 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
AU2007248656B2 (en) 2006-05-03 2013-04-04 Dana-Farber Cancer Institute, Inc. Histone deacetylase and tubulin deacetylase inhibitors
ATE537450T1 (de) 2006-06-30 2011-12-15 Schering Corp Igfbp2-biomarker
WO2008060907A2 (en) 2006-11-10 2008-05-22 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
EP2111402B1 (en) * 2007-01-05 2012-03-07 Bristol-Myers Squibb Company Aminopyrazole kinase inhibitors
JP2010515708A (ja) * 2007-01-12 2010-05-13 アブ サイエンス 代謝拮抗薬およびチロシンキナーゼ阻害剤を用いた固形癌の併用治療
MX2010003606A (es) 2007-10-01 2010-07-02 Isis Pharmaceuticals Inc Modulacion antisentido de la expresion del receptor del factor de crecimiento fibroblastico 4.
TWI557111B (zh) 2007-10-26 2016-11-11 加州大學董事會 二芳基乙內醯脲類化合物
EP2321264B1 (en) 2008-07-23 2016-05-04 President and Fellows of Harvard College Deacetylase inhibitors and uses thereof
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
AU2012271357A1 (en) 2011-06-16 2013-05-02 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20170349540A1 (en) * 2014-07-28 2017-12-07 The General Hospital Corporation Histone deacetylase inhibitors
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CA3099763A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
CN116751195B (zh) * 2023-06-21 2025-03-07 杭州科兴生物化工有限公司 联吡啶类化合物、其可药用的盐以及制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0841008A (ja) * 1994-07-29 1996-02-13 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
JP2002518380A (ja) * 1998-06-18 2002-06-25 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
EP1503996B1 (en) 2002-04-23 2008-12-24 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
HUE025353T2 (en) 2002-04-23 2016-02-29 Bristol Myers Squibb Co Pyrrolo-triazine aniline compounds as kinase inhibitors
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US6951859B2 (en) 2002-08-02 2005-10-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
NO330043B1 (no) 2011-02-07
DE60331061D1 (de) 2010-03-11
WO2004001059A2 (en) 2003-12-31
US7547711B2 (en) 2009-06-16
ES2337246T3 (es) 2010-04-22
EP1513818B1 (en) 2010-01-20
EP1513818A2 (en) 2005-03-16
IS7599A (is) 2004-12-15
PE20040581A1 (es) 2004-09-08
US7084160B2 (en) 2006-08-01
AU2003251559A8 (en) 2004-01-06
PL374272A1 (en) 2005-10-03
US20040077696A1 (en) 2004-04-22
WO2004001059A3 (en) 2004-03-04
AR040272A1 (es) 2005-03-23
EP1513818A4 (en) 2006-10-04
JP2005533808A (ja) 2005-11-10
TW200401638A (en) 2004-02-01
ATE455767T1 (de) 2010-02-15
US20060135576A1 (en) 2006-06-22
JP4477492B2 (ja) 2010-06-09
AU2003251559A1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
NO20045220L (no) Heterocykliske inhibitorer for kinaser
CY2016042I1 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
NO20050636L (no) Inhibitorer av tyrosinkinaser
NO20050072L (no) Nye inhibitorer av kinaser
DK1562589T3 (da) Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
DE60321808D1 (de) Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
EP1704145A4 (en) SELECTIVE KINASEINHIBITORS
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
AP2007004004A0 (en) Pyrrolidyl derivatives of heteroaromatic compoundsas phosphodiesterase inhibitors
DK1501508T3 (da) Inhibitorer af histondeatylase
EP1509507A4 (en) INHIBITORS OF MITOTIC KINESINE
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
EP1660436A4 (en) cathepsin inhibitors
DK1811998T3 (da) Triazoler anvendelige som inhibitorer af proteinkinaser
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
EP1651599A4 (en) TYROSINE KINASE INHIBITORS
EP1697331A4 (en) INHIBITORS OF MITOTIC KINESINE
EP1496897A4 (en) Tyrosine kinase inhibitor
EP1515727A4 (en) (HALO-BENZO CARBONYL) HETEROBICYCLIC P38 KINASE INHIBITION
DE60319836D1 (de) Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
AU2003268464A8 (en) Indole-type derivatives as inhibitors of p38 kinase
EP1697381A4 (en) INHIBITORS OF MITOTIC KINESINE

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees